文献速递妇科

不同组织学类型宫颈癌的临床病理特征与预后:一项基于人群的队列研究

Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study.
PubMed 文献 · Gynecol Oncol · 2021-11-02

该研究从监测、流行病学和最终结果(SEER)项目纳入2004至2016年确诊的39088例宫颈癌患者,分析不同组织学类型的预后差异。结果显示鳞癌最常见(27043例,74.5%),腺癌(HR=1.14,95%CI=1.09-1.20,P<0.01)和腺鳞癌(HR=1.28,95%CI=1.18-1.40,P<0.01)预后较鳞癌差,腺癌与鳞癌的预后差异仅见于II期和III期患者。

要点

  • 鳞癌占74.5%(27043例),腺癌占21.4%(7755例),腺鳞癌占4.1%(1512例)。
  • 腺癌(HR=1.14,95%CI=1.09-1.20,P<0.01)和腺鳞癌(HR=1.28,95%CI=1.18-1.40,P<0.01)预后较鳞癌差。
  • 同步放化疗患者中腺癌生存较鳞癌差(HR=1.14,95%CI=1.03-1.27,P<0.01)。

核心结论

  • 宫颈癌组织学类型的预后影响取决于肿瘤分期和治疗方式。
  • 需针对不同组织学类型和分期制定个体化治疗与随访计划。

研究设计与样本

  • 基于人群的队列研究,从监测、流行病学和最终结果(SEER)项目纳入2004至2016年确诊的39088例宫颈癌患者。
  • 采用log-rank法及单因素/多因素Cox模型,在倾向性评分匹配前后评估预后相关变量。

主要发现

  • 36310例患者中,鳞癌最常见(n=27043,74.5%),其次为腺癌(n=7755,21.4%)和腺鳞癌(n=1512,4.1%)。
  • 与鳞癌患者相比,腺癌(HR=1.14,95%CI=1.09-1.20,P<0.01)和腺鳞癌(HR=1.28,95%CI=1.18-1.40,P<0.01)患者预后显著更差。
  • 亚组分析显示腺癌与鳞癌的预后差异仅见于II期和III期患者(P<0.01)。
  • 接受同步放化疗的患者中,腺癌患者生存率较鳞癌患者显著更差(HR=1.14,95%CI=1.03-1.27;P<0.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The prognostic impact and treatment responses among cervical cancer patients with different histological types remains inconclusive. To determine the prognostic effects of different histologic types, we identified 39,088 patients with a diagnosis of cervical cancer between 2004 and 2016 from the Surveillance, Epidemiology, and End Results program. METHODS: Variables related to the prognosis of cervical cancer were evaluated using log-rank method and univariate/multivariate Cox models before and after propensity score matching. RESULT: Of the 36,310 patients, Squamous cell carcinoma (SCC) was the most common histological type (n = 27,043, 74.5%), followed by adenocarcinoma (AC, n = 7755, 21.4%) and adenosquamous carcinoma (ASC, n = 1512, 4.1%). Compared to SCC patients, patients with AC (HR = 1.14, 95%CI = 1.09-1.20, P < 0.01) and ASC (HR = 1.28, 95%CI = 1.18-1.40, P < 0.01) showed significantly poorer prognosis. Subgroup analyses indicated that the differences in prognosis between AC and SCC were only observed in stage II and III patients (P < 0.01). In patients with concurrent chemoradiotherapy, survival rates of patients with AC were significantly worse compared with similar patients with SCC (HR = 1.14, 95%CI = 1.03-1.27; P < 0.01). CONCLUSION: The prognostic impact of histologic types among patients with cervical cancer depends on tumor stages and therapeutic approaches. Tailored treatment and follow-up planning need to be developed across patients with different histological types and stages.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Meng Y, Chu T, Lin S, et al. Clinicopathological characteristics and prognosis of cervical cancer with different histological types: A population-based cohort study. Gynecol Oncol. 2021. PMID: 34740461. doi:10.1016/j.ygyno.2021.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。